Perzinfotel

Perzinfotel is a drug that was under development for the treatment of stroke and migraine. It acts as an NMDA antagonist, specifically blocking the glutamate site on the NMDA receptor, which is one of the subtypes of glutamate receptor. This makes it a noncompetitive antagonist.

History[edit | edit source]

Perzinfotel was developed by the pharmaceutical company Eli Lilly. It reached Phase II clinical trials for the treatment of acute ischemic stroke and migraine, but development was discontinued due to lack of efficacy.

Mechanism of action[edit | edit source]

Perzinfotel works by blocking the glutamate site on the NMDA receptor, one of the subtypes of glutamate receptor. This makes it a noncompetitive antagonist. The NMDA receptor is a major subtype of glutamate receptor, and it plays a key role in the transmission of electrical signals in the brain. By blocking this receptor, perzinfotel can potentially reduce the damage caused by excessive glutamate release, which is a common feature of many neurological disorders, including stroke and migraine.

Clinical trials[edit | edit source]

Perzinfotel reached Phase II clinical trials for the treatment of acute ischemic stroke and migraine. However, development was discontinued due to lack of efficacy. In the clinical trials, perzinfotel was found to be safe and well-tolerated, but it did not show significant benefits in reducing the symptoms of stroke or migraine.

See also[edit | edit source]

Perzinfotel Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.